Topics:

Ovarian Cancer

Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High AEs

Maintenance therapy with pazopanib improved progression-free survival by 5.6 months in advanced ovarian cancer patients, according to results of a new study

Ovarian Cancer

Adding the PARP inhibitor veliparib to cyclophosphamide did not improve response rates or progression-free survival in ovarian cancer.

Women with bilateral malignant ovarian germ cells tumors may still have a good prognosis and may be able to maintain fertility with conservative treatment.

ACOG recently released a Committee Opinion on the use of salpingectomy for ovarian cancer prevention in at-risk women undergoing routine pelvic surgery.

The FDA has approved olaparib, to be marketed under the name Lynparza, for the treatment of advanced ovarian cancer related to defective BRCA genes.

Researchers have identified several factors, including breastfeeding and oral contraceptives, that may decrease the risk of BRCA-associated ovarian cancer.

An oncolytic herpes simplex virus had significant efficacy against ovarian cancer when used alone and in combination with standard chemotherapy treatment.

Ovarian cancer cells were detected by collecting and testing DNA specimens taken from the tampons of ovarian cancer patients prior to surgery for a pelvic mass.

Pages

Subscribe to Ovarian Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.